Other substances

Ixazomib

A proteasome inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Ixazomib is a second-generation peptide proteasome inhibitor with antineoplastic activity (NCIt).

Ixazomib on DrugBank
Ixazomib on PubChem
Ixazomib on Wikipedia

Synonyms

CS-1657

Marketed as

NINRALO (Ixazomib citrate)

 

Structure image - Ixazomib

B([C@H](CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels
in silico 4.86

In silico screening of potential ACE2 agonists. Theoretical amelioration of ACE2 depletion by virus attachment.

 Jun/27/2020

AI-suggested references

Link Publication date
In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Apr/03/2022
Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets.
Sep/08/2021
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study
Sep/06/2020
Export (.csv)